Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2014; 5(5): 651-658
Published online Oct 15, 2014. doi: 10.4239/wjd.v5.i5.651
Published online Oct 15, 2014. doi: 10.4239/wjd.v5.i5.651
Diabetes treatment in patients with renal disease: Is the landscape clear enough?
Ioannis Ioannidis, 2nd Department of Internal Medicine, Konstantopoulio Hospital, Nea Ionia, 14233 Athens, Greece
Author contributions: Ioannidis I solely contributed to this paper.
Correspondence to: Ioannis Ioannidis, MD, PhD, Director of Diabetes Outpatient Clinic, 2nd Department of Internal Medicine, Konstantopoulio Hospital, Nea Ionia, Agias Olgas 3-5, 14233 Athens, Greece. kefion@otenet.gr
Telephone: +30-213-2057216 Fax: +30-210-2773845
Received: November 30, 2013
Revised: July 9, 2014
Accepted: July 18, 2014
Published online: October 15, 2014
Revised: July 9, 2014
Accepted: July 18, 2014
Published online: October 15, 2014
Core Tip
Core tip: Chronic kidney disease (CKD) is very often among diabetic persons. In every day clinical practice doctors worldwide have to deal with these patients and help them to achieve their metabolic goals. Despite this, many studies of antidiabetic drugs have excluded people with CKD. So, we lack solid evidence on the effectiveness and safety of these drugs. In this review I propose therapeutic algorithms for diabetic patients in different stages of CKD and clarify some questions about the use of popular antidiabetic drugs as metformin and sulfonylureas.